For non-small cell lung cancer (NSCLC), co-clinical 18F-FDG PET imaging is employed to assess the therapeutic response of combined anti-programmed death ligand 1 (PD-L1) immunotherapy and C-X-C motif chemokine receptor 2 (CXCR2) target therapy. The gene discussed is CXCR2; the disease is non-small cell lung carcinoma.